AF
CYTK icon

Allworth Financial’s Cytokinetics CYTK Stock Holding History

Allworth Financial’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46K Buy
540
+58
+12% +$4.17K ﹤0.01% 2570
2026
Q1 		$31.8K Buy
482
+47
+11% +$2.99K ﹤0.01% 2659
2025
Q4 		$27.6K Buy
435
+37
+9% +$2.3K ﹤0.01% 2591
2025
Q3 		$21.9K Buy
398
+127
+47% +$5.23K ﹤0.01% 2654
2025
Q2 		$8.95K Buy
271
+20
+8% +$696 ﹤0.01% 2948
2025
Q1 		$10.1K Buy
251
+68
+37% +$3.13K ﹤0.01% 2423
2024
Q4 		$8.57K Buy
183
+2
+1% +$104 ﹤0.01% 2499
2024
Q3 		$9.56K Buy
181
+4
+2% +$223 ﹤0.01% 2279
2024
Q2 		$9.98K Hold
177
– – ﹤0.01% 2220
2024
Q1 		$12.4K Sell
177
-162
-48% -$12.5K ﹤0.01% 2012
2023
Q4 		$28.3K Sell
339
-62
-15% -$2.25K ﹤0.01% 1444
2023
Q3 		$11.8K Buy
401
+76
+23% +$2.53K ﹤0.01% 1783
2023
Q2 		$10.6K Hold
325
– – ﹤0.01% 1845
2023
Q1 		$11.4K Buy
+325
New +$13.3K ﹤0.01% 1745
2022
Q4 		– Sell
-26
Closed -$1K – 3049
2022
Q3 		$1K Buy
+26
New +$1.25K ﹤0.01% 2352

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allworth Financial's CYTK Position: Q2 2026 in Review

Allworth Financial increased its Cytokinetics (CYTK) stake by 12% in Q2 2026, buying an estimated $4.17K and bringing the position to 540 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #2570.

Allworth Financial first reported a position in CYTK in Q3 2022 and has held it in 15 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Allworth Financial held 540 shares of Cytokinetics worth $46K as of Q2 2026.
  • Allworth Financial bought 58 Cytokinetics shares in Q2 2026, an estimated $4.17K.
  • Cytokinetics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2570 holding.
  • Allworth Financial first reported a position in Cytokinetics in Q3 2022 and has held it in 15 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.